AI Biotech Acquires Immunotox
Friday, March 21, 2014
AIBioTech has acquired ImmunoTox, Inc, a Richmond-based, contract research firm that focuses on immunotoxicology and immunopharmacology studies done principally for customers in the pharmaceutical, biotechnology, and manufacturing sectors. The acquisition adds to the comprehensive biotechnology services that AIBioTech currently provides to its clients by performing assessments that examine the effects of drugs, chemicals, biologics, and other physical agents on the immune system.
Founder and Chief Executive Officer of ImmunoTox Kimber White, Ph.D. said, "We are looking forward to the opportunities that come with aligning ourselves with AIBioTech. "Our capabilities complement AIBioTech’s existing assay design and immunology services very well.”
White will continue with AIBioTech as a paid consultant. Other key employees of ImmunoTox Inc have also accepted employment and together with acquisition of all necessary instrumentation, the ImmuonTox division will be able to continue its service offerings unabated. ImmunoTox will operate as a division of AIBioTech.
"We intend to leverage the expertise of ImmunoTox into expanded service offerings for our current customers including for the first time, flow cytometry” said AIBioTech President and Chief Scientific Officer Robert B. Harris, Ph.D. "The ability to monitor the immune response of the host organism is a critical component along the path of drug (and chemical) development, and by adding these services to our research support repertoire, AIBioTech becomes even more competitive as the preferred full-service contract research organization.